ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
ALBERT LABS INTL. CORP. (VB50) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALBERT LABS INTL. CORP. (VB50) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALBERT LABS INTL. CORP. - Net Assets Trend (None–None)
This chart illustrates how ALBERT LABS INTL. CORP.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALBERT LABS INTL. CORP. (None–None)
The table below shows the annual net assets of ALBERT LABS INTL. CORP. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALBERT LABS INTL. CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALBERT LABS INTL. CORP. Competitors by Market Cap
The table below lists competitors of ALBERT LABS INTL. CORP. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ITWO
BATS:ITWO
|
$380.67K |
|
Germina Agribusiness SA
RO:SEOM
|
$380.77K |
|
TOURMALINE OIL
BE:08T
|
$381.02K |
|
FLUOR (NEW) - Dusseldorf Stock Exchang
DU:FLU
|
$381.27K |
|
TOSHF
OTCGREY:TOSHF
|
$380.45K |
|
KEPCO Plant Service & Engineering Co. Ltd.
KQ:051600
|
$380.29K |
|
AMKOR TECHNOLOGY - Dusseldorf Stock Exchang
DU:AMK
|
$380.19K |
|
AJAX RESOURCES PLC LS-01
F:Z8E
|
$380.13K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALBERT LABS INTL. CORP.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALBERT LABS INTL. CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALBERT LABS INTL. CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALBERT LABS INTL. CORP.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALBERT LABS INTL. CORP. (VB50) | €- | N/A | N/A | $380.45K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |